Captura Biopharma

Captura Biopharma, LLC is an emerging biotechnology company engaged in the development and commercialization of heavy metal chelators for treating internal radionuclide contamination and heavy metal poisoning. Its lead chelation candidate, C2E2, will be the world’s first oral treatment targeting internal radiation contamination and has been proven effective in studies targeting specific heavy metals, particularly americium, plutonium, and lead. UNICEF estimates that one-third of children worldwide suffer from lead poisoning and its associated neurological damage. Captura also intends to address indications for cadmium poisoning and rare earth metal poisoning. Increased investment in electric vehicles, solar energy, and lithium-ion batteries will drive the use of cadmium and significant toxic exposure during manufacturing and disposal processes.